# Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

> **NCT05113966** · PHASE2 · TERMINATED · sponsor: **G1 Therapeutics, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Trilaciclib
- **DRUG:** Sacituzumab Govitecan-hziy

## Key facts

- **NCT ID:** NCT05113966
- **Lead sponsor:** G1 Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-08
- **Primary completion:** 2023-11-10
- **Final completion:** 2024-06-13
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** The Sponsor decided to close enrollment to the study on Feb 14, 2023, in order to reallocate resources to other ongoing trilaciclib clinical trials.
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113966, "Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05113966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*